Information Provided By:
Fly News Breaks for September 14, 2018
SRPT
Sep 14, 2018 | 06:19 EDT
BofA/Merrill analyst Tazeen Ahmad reinstated Sarepta with a Buy and $199 price target saying the company has a diversified pipeline of assets that address an under met need in the treatment of rare muscular dystrophies.
News For SRPT From the Last 2 Days
There are no results for your query SRPT